networking-event-for-personalised-digital-health-innovations-in-horizon-2020

1. UK Research and Innovation
Horizon 2020
SC1-2018-RTD Single stage results
Jerome de Barros
Horizon 2020 Health NCP

2. UK Research and Innovation
- Horizon 2020 basics
- UK Participation and guarantees
- SC1 2018 call topics results
- Overview of 2019 call topics

3. Innovate UK: the UK’s innovation agency
▪ Innovate UK drives productivity and growth by supporting
businesses to realise the potential of new technologies,
develop ideas and make them a commercial success.
▪ To stay competitive as an advanced economy, we need to do
things that others cannot do, or to do things in different and
better ways.

4. Innovate UK: the UK’s innovation agency
We help in three ways
FUND
Grants to help companies:
- Explore the potential of a new
area
- Develop new products,
processes or services
- Evaluate potential new business
models
- Accelerate the process of going
from idea to commercial success
CONNECT
Linking companies to:
- Potential collaborators
- Relevant expertise
- Access to equipment and facilities
- Overseas collaborations
- Regional presence
COLLABORATE
- Through our network of Catapults and
Centres

5. Horizon 2020 in a nutshell
▪ The main European Union programme for research and innovation for 2014-2020 (80bn EUR
from 2014 to 2020)
▪ UK has been the most successful country in Health competitions since 2014
- 800+ organisations funded since 2014 drawing nearly EUR 500m
▪ Most funding opportunities support collaborative R&I projects (with some exceptions, i.e SME
Instrument)
▪ All participants (universities, businesses, not-for-profit organisations, etc.) are eligible and the
same funding rate is applicable to all activities in the same project: one project – one rate for
all partners
▪ Time to Grant from submission: up to 8 months

6. Societal Challenge 1 – Funding & Participation

7. SC1 – Funding by UK region

8. UK Research and Innovation
UK participation eligibility and
guarantees

9. UK Participants eligibility and guarantees
▪ UK partners are fully eligible to all Horizon 2020 instruments at least while the UK is still a
member of the EU and encourage to continue to apply to the programme in the usual way.
▪ The UK and EU’s intention is that the eligibility of UK researchers and businesses to
participate in Horizon 2020 will remain unchanged for the remaining duration of the
programme – as set out in the Withdrawal Agreement.
▪ The European Commission added clarifications in its latest version of the H2020 Expert briefing:
http://ec.europa.eu/research/participants/data/support/expert/h2020_expert-briefing_en.pdf

10. UK Participants eligibility and guarantees
▪ In the unlikely case of a no-deal scenario, UK researchers and businesses will be able to apply to
and participate in all those Horizon 2020 calls open to third country participants from the date
of exit, with funding provided via the extended guarantee (with the UK Treasury underwriting the
payments of awards, even when specific projects continue beyond the UK’s departure from the
EU).
▪ Third country participation does not extend to European Research Council (ERC) grants, some
Marie Sklodowska-Curie Actions (MSCA) and the SME instrument.
▪ UK Research and Innovation (UKRI) has been chosen to manage the underwrite delivery
▪ UK recipients of Horizon 2020 funding will be invited by UKRI to register their details on a
dedicated portal on the GOV.UK website expected to go live in the autumn

11. UK Participants eligibility and guarantees
▪ In the unlikely case of a no-deal scenario, UK researchers and businesses will be able to apply to
and participate in all those Horizon 2020 calls open to third country participants from the date
of exit, with funding provided via the extended guarantee (with the UK Treasury underwriting the
payments of awards, even when specific projects continue beyond the UK’s departure from the
EU).
▪ Third country participation does not extend to European Research Council (ERC) grants, some
Marie Sklodowska-Curie Actions (MSCA) and the SME instrument.
▪ UK Research and Innovation (UKRI) has been chosen to manage the underwrite delivery
▪ UK recipients of Horizon 2020 funding will be invited by UKRI to register their details on a
dedicated portal on the GOV.UK website expected to go live in the autumn

12. UK Participants eligibility and guarantees
▪ BEIS confirmed that UK entities will be able to assume coordination tasks of Horizon 2020
projects, even in the unlikely event of a no-deal scenario, with the guarantee to cover costs for
coordination tasks if UK participant opts to be the coordinator

13. UK Research and Innovation
SC1 2018 call topics results

14. SC1-2018-RTD Single stage results*
Total Participants Total Beneficiaries
Total Req. Budget Total Req. Budget
UK 313 8.4% €195.64m 9.4% 73 9.2% €34.97m 10.3%
DE 393 10.6% €288.16m 13.8% 100 12.6% €55.38m 16.3%
NL 279 7.5% €214.37m 10.3% 71 8.9% €44.99m 13.2%
FR 291 7.8% €163.36m 7.8% 69 8.7% €33.40m 9.8%
ES 379 10.2% €220.03m 10.5% 68 8.6% €29.11m 8.6%
IT 335 9,0% €197.36m 9.5% 58 7.3% €30.74m 9.0%
Total 3,710 100% €2,085.6m 100.0% 794 100.0% €339.71m 100.0%
* Call topic BHC-04-2018 Rare Disease European Joint Programme Cofund was excluded as the UK would not take part in this programme

15. Key points
▪ UK #2 in number of organisations selected for funding (Germany #1, Netherlands #3)
▪ UK #3 in total EU requested contribution for funded participants (Germany #1, Netherlands #2)
▪ Number of proposals received: 322
▪ Number of proposals selected for funding: 63
▪ Number of selected proposals coordinated by UK: 4 (NL: 14, ES: 10, DE: 9)
▪ UK businesses funded:
- Cell Therapy Catapult Ltd (€975,625.00)
- A2F Associates Ltd (€718,845.00)
- Labman Automation Ltd (€395,420.00)
- Cyprotex Discovery Ltd (€351,444.00)
- Atlantis Healthcare UK Limited (€240,000.00)
- PD Neurotechnology Ltd (€237,500.00)
- Clinicageno Ltd (228,375.00)

16. Call topics included in this comparison
Call topic Budget (€m)
SC1-BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction,
prevention and treatment of disease (RIA)
50.00
SC1-BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised
medicine approaches (RIA)
40.00
SC1-BHC-09-2018: Innovation platforms for advanced therapies of the future (RIA) 54.00
SC1-BHC-16-2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of evidence-based health interventions at population level for
the prevention and management of hypertension and/or diabetes (RIA)
20.00
SC1-BHC-18-2018: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean
States (CELAC) (RIA)
25.00
SC1-BHC-21-2018: Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV) in patients with mono-, co-infections and/or comorbidities
in the context of fostering collaboration with the Russian Federation (RIA)
10.00
SC1-BHC-23-2018: Novel patient-centred approaches for survivorship, palliation and/or end-of-life care (RIA) 44.00
SC1-BHC-26-2018: HTA research to support evidence-based healthcare (RIA) 10.00
SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (RIA) 52.00

17. Call topics included in this comparison
Call topic Budget (€m)
SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine (CSA) 8.00
SC1-HCO-02-2018: Data integration and data-driven in-silico models for enabling personalised medicine - a European standardization
framework (CSA)
2.00
SC1-HCO-04-2018: ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan (JPND) (CSA) 5.00
SC1-HCO-05-2018: Strengthening regulatory sciences and supporting regulatory scientific advice (CSA) 2.00
SC1-HCO-06-2018: Establishment of an International Network of Social Sciences Research Centres to help address governance and other
challenges in the preparedness for and the response to infectious threats (CSA)
3.00
SC1-HCO-08-2018: Creation of a European wide sustainable clinical research network for infectious diseases (CSA) 3.00
SC1-HCO-09-2018: Building international efforts on population and patient cohorts (CSA) 2.00
SC1-HCO-10-2018: Coordinating European brain research and developing global initiatives (CSA) 2.00
SC1-HCO-11-2018: Strategic collaboration in health research and innovation between EU and China 1.00
SC1-HCO-12-2018: Innovation in healthcare - a CSA towards using pre-commercial procurement and public procurement of innovative
solutions in healthcare systems
2.00
SC1-HCO-13-2018: Setting the priorities for a European environment, climate and health research agenda 3.00

18. SC1-2018-CNECT Single stage results*
Total Participants Total Beneficiaries
Total Req. Budget Total Req. Budget
UK 188 6.8% €92.16m 7.1% 14 9.2% €6.04m 4.3%
DE 279 10.1% €162.31m 12.4% 41 12.6% €35.03m 24.8%
NL 157 5.7% €83.80m 6.4% 16 8.9% €6.14m 4.3%
FR 142 5.2% €76.80m 5.9% 17 8.7% €8.56m 6.1%
ES 334 12.1% €147.22m 11.3% 37 8.6% €14.68m 10.4%
IT 357 13.0% €154.01m 11.8% 31 7.3% €12.17m 8.6%
Total 2,755 100.0% €1,307.1m 100.0% 301 100.0% €141.26m 100.0%
* Call topic BHC-04-2018 Rare Disease European Joint Programme Cofund was excluded as the UK would not take part in this programme

19. Key points
▪ UK #6 in number of organisations selected for funding
▪ UK #6 in total EU requested contribution for funded participants
▪ Number of proposals received: 216
▪ Number of proposals selected for funding: 24
▪ Number of selected proposals coordinated by UK: 2 (DE: 5, ES: 5, EL: 5)
▪ UK businesses funded:
- Information Catalyst for Enterprises Ltd (€449,625.00)
- Spark Works ITC (€442,812.00)
- Tech Inspire Ltd (€311,250.00)
- Samsung Electronics Ltd (€290,125.00)
- Trust-IT Services Ltd (€205,187.50)

20. Call topics included in this comparison
Call topic Budget (€m)
SC1-DTH-03-2018: Adaptive smart working and living environments supporting active and healthy ageing (RIA) 25.00
SC1-DTH-07-2018: Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based
environments (RIA)
35.00
SC1-DTH-08-2018: Prototyping a European interoperable Electronic Health Record (EHR) exchange (RIA) 30.00
SC1-HCC-01-2018: Supporting investment in smart living environments for ageing well through certification (CSA) 1.00
SC1-HCC-03-2018: Support to further development of international cooperation in digital transformation of health and care (CSA) 2.00
SC1-HCC-04-2018: Digital health and care services – support for strategy and (early) adoption (CSA) 3.00
SC1-HCC-05-2018: Support to a Digital Health and Care Innovation initiative in the context of Digital Single Market strategy (CSA) 4.00
SU-TDS-02-2018: Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect privacy/data/infrastructures (RIA) 35.00
SU-TDS-03-2018: Raising awareness and developing training schemes on cybersecurity in hospitals (CSA) 1.00

21. UK Research and Innovation
Overview of 2019 call topics

22. BHC-07-2019: Regenerative medicine: from new insights to
new applications
▪ Focus: Translational research to develop regenerative processes for major human diseases
and conditions addressing unmet clinical needs of large patient groups
▪ Must be based on new approaches (i.e. genome editing or gene therapy, transdifferentiation or in
vivo reprogramming, cell therapy and transplantation, 3D bioprinting, organoids or use of
combined products, etc.)
▪ The project may focus on any step(s) on the innovation chain, from early testing and
characterization of regenerative mechanisms to preclinical research, proof of concept or clinical
trial
▪ Research and Innovation Action / Size of projects: EUR 6 to 8 million (total budget: EUR 50m)

23. BHC-10-2019: Innovation Procurement: Next generation
sequencing (NGS) for routine diagnosis
▪ Focus: Solutions supporting the implementation of NGS platforms and use of NGS tests in in
routine diagnostics for personalised medicine, including:
▪ NGS tests,
▪ clinically validated procedures (including sex analysis),
▪ quality assurance schemes,
▪ tools and methods for data collection, management, analysis and interpretation
▪ Input from initiatives like the EJP Cofund on rare diseases and ERNs should be considered
▪ PCP Pre-Commercial Procurement / Size of projects: EUR 9 to 11 million (total budget: EUR
50m)

24. BHC-10-2019: Innovation Procurement: Next generation
sequencing (NGS) for routine diagnosis
▪ PCP to steer the development of solutions towards concrete public sector needs,
whilst comparing/validating alternative solution approaches from various vendors
▪ PPI to act as launching customer / early adopter / first buyer of Innovative
commercial end-solutions newly arriving on the market

25. BHC-10-2019: Innovation Procurement: Next generation
sequencing (NGS) for routine diagnosis
▪ PCP actions (max 90% funding rate)
▪ Provide EU co-financing for an actual PCP procurement (one joint PCP
procurement per PCP action) + for related coordination and networking
activities (e.g. to prepare, manage and follow-up the PCP procurement)
▪ Requested reimbursement for coordination and networking activities can
comprise max 30% (for PCP) of total requested grant
▪ Minimum 3 independent participants from 3 different MS or AC, of which
minimum 2 public procurers (buyers group) from 2 different MS or AC
▪ https://ec.europa.eu/digital-single-market/en/news/calls-eu-funding-opportunities-
pre-commercial-procurement-and-public-procurement-innovative

26. BHC-13-2019: Mining big data for early detection of infectious
disease threats driven by climate change and other factors
▪ Focus: Development and demonstration of feasibility of tools for for early detection of infectious
disease threats:
▪ Technologies allowing the pooling, access, analysis and sharing of relevant data, including
next generation sequencing NGS tests;
▪ innovative bio-informatics and modelling methodologies that enable risk modelling and
mapping;
▪ analytical tools for early warning, risk assessment and monitoring of (re-)emerging
infectious disease threats
▪ Proposals should ensure a one health approach and collaboration with other relevant current
future initiatives (EJP on One Health, SFS-36-2017 projects, etc.)
▪ Research & Innovation action / Size of projects: EUR 12 to 15 million (total budget: EUR 30m)

27. BHC-13-2019: Mining big data for early detection of infectious
disease threats driven by climate change and other factors
▪ Solutions should be compatible with existing European initiatives, and should remain available
for public use at the end of the project at a reasonable cost:
▪ European Centre for Disease Prevention and Control: https://ecdc.europa.eu/en/home
▪ Diseases and laboratory networks (i.e. antimicrobial resistance, influenza, etc.)
▪ WHO Global Public Health Intelligence Network (GPHIN)

28. BHC-28-2019: The Human Exposome Project: a toolbox for assessing
and addressing the impact of environment on health
▪ Focus: Development of solutions supporting the collection, combination and analysis of large
data sets offering new possibilities to understand the contribution of environmental factors to the
global health burden of common chronic diseases through:
▪ agnostic evaluation of the role of multiple and unknown exposures;
▪ assessment of individual exposure to multiple stressors;
▪ integration of external exposome data with cross-omics responses and (epi)genetic data
▪ Innovation and connections with industry are expected in the areas of sensor development
(external exposome), omics technology and novel biomarker development (internal exposome),
bioinformatics, and data processing and management
▪ Research & Innovation action / Size of projects: EUR 8 to 12 million (total budget: EUR 50m)

29. BHC-28-2019: The Human Exposome Project: a toolbox for assessing
and addressing the impact of environment on health
▪ Well-designed retrospective epidemiological studies may be included and proposals may
envisage the creation of a prospective Europe-wide exposomics cohort and biobank, integrating
behavioural, socio-economic factors and clinical records.
▪ BBMRI-ERIC - European research infrastructure for biobanking: http://www.bbmri-eric.eu
▪ CORBEL; http://www.corbel-project.eu/home.html

30. BHC-31-2019: Pilot actions to build the foundations of a human
cell atlas
▪ Focus: Demonstrate the utility of an interdisciplinary technological/biological platform to generate
and integrate standardised molecular, cellular, biochemical and other data sets, characterising
single cells or their nuclear components, their interactions and/or spatial location in tissues
from one human organ BUT Platforms supporting analysis of tissues from more than one organ
are also in scope.
▪ The primary focus should be on healthy tissues, though comparison between healthy and
diseased tissues could be appropriate
▪ Projects should have a duration of two years
▪ Research and Innovation Action / Size of projects: EUR 3 to 5 million (total budget: EUR 15m)

31. BHC-31-2019: Pilot actions to build the foundations of a human
cell atlas
▪ Human Cell Atlas: comprehensive reference maps of all human cells for both understanding
human health and diagnosing, monitoring, and treating disease
▪ https://www.humancellatlas.org
▪ Weekly call focused on match-making consortium members:
https://www.humancellatlas.org/news/18

32. BHC-32-2019: Towards a next generation influenza vaccine to
protect citizens worldwide – an EU-India collaboration
▪ Focus: Advance the development and validation of next generation influenza vaccine
candidate(s) with improved efficacy and safety, duration of immunity, and reactivity against an
increased breadth of influenza strains (non-seasonal new strains)
▪ Proposals should cover at least pre-clinical and/or early clinical research, selecting promising
vaccine candidate(s), supporting their proof of concept, showcasing new pre-clinical or clinical
knowledge
▪ The approach taken should include validation of one or more candidate vaccine(s) in a
human challenge model of influenza, and/or work to improve the influenza human challenge
model itself
▪ Research and Innovation Action / Size of projects: EUR 6 to 10 million (total budget: EUR 15m
from EC + EUR 15m from Indian authorities)

33. BHC-32-2019: Towards a next generation influenza vaccine to
protect citizens worldwide – an EU-India collaboration
▪ Indian organisations must fill in a different template: http://www.dbtindia.nic.in/wp-
content/uploads/DBT-European-Commission-H2020-call-2017-18.pdf
▪ Proposals submitted to both agencies (EC participant portal + Indian authorities) who are both
evaluating proposals
▪ Consortium composed of at least 3 partners from MS and AC + at least 3 partners from India
▪ It is advised for the coordinator to be from a MS or AC, and to identify a Scientic coordinator for
Indian organisations participating

34. DTH-01-2019: Big data and Artificial Intelligence for monitoring
health status and quality of life after the cancer treatment
▪ Focus: Big data and AI-driven solutions to better acquire, manage, share, model, process and
exploit big data to more efficiently:
- Monitor health status of individual patients
- Provide overall actionable insights at the point of care
- Improve quality of life after the cancer treatment
▪ Proposals should address relevant health economic issues, use patient reported outcome and
experience measures (PROMs and PREMs) and take into account the relevant social aspects of
health status and quality of life after cancer treatment
▪ Information can be collected from 1) traditional sources of health data (cohorts, comprehensive
electronic health records or clinical registries, incl. genetic data, validated biomarkers for
remission), from 2) new sources of health data (mobile health apps and wearables) and from 3)
sources created for other purposes such as environmental data
▪ Research and Innovation Action / Size of projects: EUR 3 to 5 million (total budget: EUR 35m)

35. DTH-05-2019: Large scale implementation of digital innovation
for health and care in an ageing society
▪ Focus: Specify, purchase and deploy on a large-scale ICT based solutions (made up of services
and ICT products to enable the provision of services) for active and healthy ageing across
different regions in Europe.
▪ Must be in line with the priority actions of the EIP on AHA Scaling-up Strategy: http://www.scale-
aha.eu/2016-twinnings.html
▪ Proposals must contribute with good outcome-based practices that are impact measured
according to the MAFEIP: https://www.mafeip.eu
▪ Public Procurement of Innovative solutions (PPI) / Size of projects: EUR 2 to 5 million (total
budget: EUR 10m)

36. DTH-05-2019: Large scale implementation of digital innovation
for health and care in an ageing society

37. DTH-05-2019: Large scale implementation of digital innovation
for health and care in an ageing society
▪ PPI actions (max 35% funding rate)
▪ Provide EU co-financing for the actual PPI procurement(s) (one joint
procurement or several separate but coordinated PPI procurements per
PPI action) + for related coordination and networking activities (e.g. to
prepare, manage and follow-up the PPI procurement(s))
▪ Minimum 3 independent participants from 3 different MS or AC, of which
minimum 2 public procurers (buyers group) from 2 different MS or AC
▪ https://ec.europa.eu/digital-single-market/en/news/calls-eu-funding-opportunities-
pre-commercial-procurement-and-public-procurement-innovative

38. DTH-09-2019: Scaling up the univocal Identification of
Medicinal Products
▪ Focus: Design and implementation of an IT solution enabling and fostering the use of a common
EU medicinal Product repository (ISO IDMP compliant) to fulfil the ePrescription/eDispensation in
a cross-border setting use case.
▪ Ensure validation of contents, error mitigation, linkage of the EU SPOR database with the
ePrescription/eDispensing systems, updates and mappings to other systems for at least 5
Member States' organisations
▪ Members of the Consortium should include a wide range of relevant stakeholders and experts
including inter alia Pharmacists, National Competent Authorities, IT Integrators, producers of
ePrescribing, clinical record systems.
▪ Synergies with actions and activities supported by different programmes and policy initiatives of
the Commission should be encouraged and resources from previous European projects should
be considered
▪ Innovation Action / Size of projects: EUR 5 to 8 million (total budget: EUR 19m)

39. DTH-11-2019: Large Scale pilots of personalised & outcome
based integrated care
▪ Focus: Large-scale pilots for deployment of trusted and personalised digital solutions dealing with
Integrated Care
- Target group: older individuals facing permanently or temporarily reduced functionality and
capabilities
- Goal: supporting and extending healthy and independent living
▪ Expected outcomes (in priority):
- Efficiency gains in terms of resource utilization and coordination of care
- Flexibility and replicability of service delivery patterns
- Ensuring secure and efficient sharing and processing of all data and information
- Improvement of quality of life (patients but not only) and working conditions of personnel
▪ Innovation Action / Size of projects: EUR 4 to 6 million (total budget: EUR 20m)